Nuvation Bio Q3 net loss narrows 25% year over year to $41.9 million

Bitget2026/11/04 21:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nuvation Bio’s third-quarter 2026 net loss narrowed 25% year over year to $41.9 million.
Total revenue more than tripled year over year to $44.95 million.
IBTROZI net product revenue rose 18% quarter over quarter to $27.5 million, reflecting continued adoption and treatment durability.
Cash, cash equivalents and marketable securities totaled $663.4 million at September 30, 2026.
The FDA cleared an IBTROZI label update showing longer response duration and granted safusidenib Fast Track designation for IDH1-mutant glioma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611041605PR_NEWS_USPR_____NY89067) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nuvation Bio Q3 net loss narrows 25% year over year to $41.9 million

You may also like

Crypto prices